|
1) Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther. 2000; 22: 1186-203
|
|
|
|
2) Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol. 2005; 16: 474-81
|
|
|
|
|
|
3) Bangalore S, Shahane A, Parkar S, et al. Compliance and fixed-dose combination therapy. Curr Hypertens Rep. 2007; 9: 184-9
|
|
|
|
|
|
4) Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet. 1999; 353: 2008-13
|
|
|
|
|
|
5) Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens. 2007; 20: 311-8
|
|
|
|
|
|
6) Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001; 14: 491-503
|
|
|
|
|
|
7) Jinno T, Iwai M, Li Z, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension. 2004; 43: 263-9
|
|
|
|
|
|
8) Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006; 113: 1213-25
|
|
|
|
|
|
9) Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004; 17: 793-801
|
|
|
|
|
|
10) 猿田享男, 他. 日本における降圧薬合剤の歴史・変遷—ARB/ 利尿薬合剤誕生の経緯—. 血圧. 2006; 13: 1297-300
|
|
|
|
|
11) Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006; 29: 2592-7
|
|
|
|
|
|
12) Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004; 43: 963-9
|
|
|
|
|
|
13) Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005; 95: 29-35
|
|
|
|
|